RSV is a leading cause of pneumonia in the elderly.
European regulators have approved the region's first vaccine for respiratory syncytial virus (RSV), which causes thousands of hospitalisations and deaths annually.
The shot, called Arexvy, is made by British drugmaker GSK and is designed to protect people aged 60 and over.
RSV typically causes cold-like symptoms, but is a leading cause of pneumonia in toddlers and the elderly.
The complex molecular structure of the virus and safety concerns with previous vaccine attempts had stymied efforts to successfully develop a shot since the virus was first discovered in 1956.
The approval this morning by the European Commission, which follows a recent endorsement from the European Medicines Agency, comes about a month after the US health regulator the gave Arexvy the green light.
The availability of the vaccine in Europe will depend on national recommendations and reimbursement discussions, but the first launches are expected this autumn ahead of the 2023/2024 RSV season, GSK said in a statement.
The company said it does not expect a significant rollout in Europe this year
Wholesale Electricity Prices 56.2% Higher Than Last Year
Reactions From Maynooth Students As Leaving Certificate Results Released
"Government Making Our Lives Hugely Difficult": Pressure Mounts On HSE To Approve Friedreich's Ataxia Drug
Government Leaders Agree To Not Increase Excise Duty For Fuel Next Month
Over 600 Extra Yearly Places Announced For Third Level Healthcare Courses
Four Men Arrested Over Numerous Burglaries During Garda Operation In West Dublin
Over 70,000 Students To Receive Leaving Certificate Results Today
Irish Rail Re-Introducing Tea Trolleys For Dublin/Galway Services As Part Of Pilot Project
